| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032706A2 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | WO2001032705A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032693A2 Trp-protein-related mtr1 protein and dna sequence coding therefor |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032685A2 Gene expression directed by a super-psa promoter |
| 05/10/2001 | WO2001032683A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032631A2 Heterocyclic cytotoxic agents |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032215A1 Antiviral agent for use in treatment of cancer |
| 05/10/2001 | WO2001032209A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | WO2001032208A1 Adjuvanted genetic vaccines |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032192A1 Active substance in ganoderma lucidum extract and drugs, health foods and cosmetics containing the same |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032155A2 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2001 | WO2001032149A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032139A2 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001016304A3 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/10/2001 | WO2001007480A3 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/10/2001 | WO2001007469A3 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 05/10/2001 | WO2001007418A3 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 05/10/2001 | WO2001001922A3 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/10/2001 | WO2001000869A3 Arrays of catalytic or pre-catalytic nucleic acids |
| 05/10/2001 | WO2001000652A3 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS |
| 05/10/2001 | WO2000078327A3 Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000075191A3 Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000072666A3 USE OF TRANSGENIC MICE LACKING JunB EXPRESSION IN THE MYELOID LINEAGE |
| 05/10/2001 | WO2000067800A3 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000061635A3 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| 05/10/2001 | WO2000033888A9 Prodrug compounds and process for preparation thereof |
| 05/10/2001 | WO1999002514A3 Epothilone derivatives |
| 05/10/2001 | US20010001104 Thienopyridine compounds, their production and use |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | US20010001041 Homogenizing a tissue in a nondenaturing aqueous solvent to obtain particles; aqueous solvent extraction; separation of solid and liquid; fractionating and purifying; inhibitors of matrix metalloprotease and angiogenesis; antitumor agents |
| 05/10/2001 | DE19954229A1 New epothilone derivatives, useful for treating malignant tumors such as ovarian, stomach, colon, breast and lung carcinoma, acute lymphocytic and myelocytic leukemia and chronic inflammatory diseases such as psoriasis |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19951960A1 Verfahren zur Herstellung von Ulkustherapeutika A process for preparing Ulkustherapeutika |
| 05/10/2001 | DE19951795A1 Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen Use of parvoviruses to improve the general condition in cancer patients or patients with chronic or consumptive diseases |
| 05/10/2001 | CA2390182A1 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | CA2389964A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389686A1 Adjuvanted genetic vaccines |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389666A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389574A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389335A1 Gene expression directed by a super-psa promoter |
| 05/10/2001 | CA2389312A1 Heterocyclic cytotoxic agents |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2389147A1 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | CA2388955A1 Recombinant fusion molecules |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388159A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387799A1 19 human secreted proteins |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/09/2001 | EP1097989A2 Ndr phosphokinase |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097937A1 N-acyl derivatives of the LL-E33288 antitumor antibiotics |
| 05/09/2001 | EP1097921A1 Phenylhydrazines |